eligibility_summary
Adults ≥18 with untreated DLBCL (NOS), high‑grade B‑cell (NOS or MYC+BCL2), or T cell/histiocyte‑rich LBCL, stage II bulky, III, or IV, ECOG ≤2, measurable disease, adequate organ/marrow function, and anthracycline‑ineligible (age ≥80, frail/unfit, EF 30–<50%, NYHA I–II, or prior anthracycline). Exclude: CNS lymphoma, recent/active other cancer, uncontrolled HIV/HBV/HCV/infections, major cardiac/ECG disease, recent stroke/seizure, autoimmune/pneumonitis, high‑dose steroids, prior epcoritamab, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 single-arm trial in newly diagnosed DLBCL (older/frail or anthracycline-ineligible) testing epcoritamab plus R-miniCVP. Epcoritamab: subcutaneous bispecific T-cell–engaging IgG1 antibody (CD3×CD20) that redirects cytotoxic T cells to kill CD20+ B cells. Rituximab: chimeric anti‑CD20 monoclonal antibody depleting B cells via ADCC, CDC, and apoptosis. Cyclophosphamide: alkylating agent causing DNA crosslinks and cytotoxicity in proliferating lymphoma cells. Vincristine: vinca alkaloid inhibiting microtubule polymerization, leading to mitotic arrest. Prednisone: glucocorticoid inducing apoptosis in lymphoid cells and anti-inflammatory effects. Cells/pathways targeted: CD20+ malignant B cells, T-cell activation via CD3, DNA damage/crosslink repair, mitotic spindle function, and glucocorticoid receptor signaling.